Prevalence of metabolic syndrome in women with rheumatoid arthritis and effective factors

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 8, 2014, Pages 2258-2265

  Bilecik, Nilüfer Aygün ^a   Tuna, Serpil ^b   Samancı, Nehir ^b   Balcı, Nilüfer ^b   Akbaş, Halide ^b  

^a Sinop Ataturk State Hospital   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

HOMA IR; Insulin resistance; Metabolic syndrome; MTX; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MORBIDITY; PREVALENCE; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

EID: 84907195278     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Henry RR. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clin Ther 2003; 25 Suppl B: B47-63.
2. Masharani U, Germen MS. Pancreatic hormones and diabetes mellitus. In: Greenspan FS, ed. Basic and Clinical Endocrinology. The McGraw-Hill Companies. 7th edn. New York, 2004. pp. 646-658.
3. Ferraz-Amaro I, Gonzalez-Juanatey C, Lopez-Mejias R, Riancho-Zarrabeitia L, Gonzalez-Gay MA. Metabolic syndrome in rheumatoid arthritis. Mediators of Inflammation 2013: 710928.
4. Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 2002; 16: 707-722.
5. Bacon PA. Extra-articular rheumatoid arthritis. Arthritis and Allied Conditions. 13th edn. Pennsylvania: Williams and Wilkins; vol 71.
6. Meune C, Touzé E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009; 48: 1309-1313.
7. Cavagna L, Boffini N, Cagnotto G, Inverardi F, Grosso V, Caporali R. Atherosclerosis and rheumatoid arthritis: more than a simple association. Mediators Inflamm 2012; 2012: 147354.
8. Zhang J, Fu L, Shi J, Chen X, Li Y, Ma B, Zhang Y. The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies. PLoS One 2013; 8: e78151.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
10. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
11. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-1062.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
13. Gremese E, Ferraccioli G. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 2011; 10: 582-589.
14. Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, Michael Stein C. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 208-214.
15. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD, Ganotakis ES, Boumpas DT. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, stu-dy. Ann Rheum Dis 2007; 66: 28-33.
16. Dodani S, Henkhaus R, Wick J, Vacek J, Gupta K, Dong L, Butler MG. Metabolic syndrome in South Asian immigrants: more than low HDL requiring aggressive management. Lipids Health Dis 2011; 10: 45.
17. Dao HH, Do QT, Sakamoto J. Increased frequency of metabolic syndrome among Viet-namese women with early rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2010; 12: R218.
18. Wasko MC, Kay J, Hsia EC, Rahman MU. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken) 2011; 63: 512-521.
19. Shahin D, Eltoraby E, Mesbah A, Houssen M. Insulin resistance in early untreated rheumatoid arthritis patients. Clin Biochem 2010; 43: 661-665.
20. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Fernando Costa. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Crit Pathw Cardiol 2005; 112: 2735-2752.
21. Lim S, Lee HK, Kimm KC, Park C, Shin C, Cho NH. C-reactive protein level as an independent risk factor of metabolic syndrome in the Korean population CRP as risk factor of metabolic syndrome. Diabetes Res Clin Pract 2005; 70: 126-133.
22. Anand SS, Razak F, Yi QL, Davis B, Jacobs R, Vuksan V, Lonn E, Teo K, McQueen M, Yusuf S. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol 2004; 24: 1509-1515.
23. Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403-1410.
24. Rostom S, Mengat M, Lahlou R, Hari A, Bahiri R, Hajjaj-Hassouni N. Metabolic syndrome in rheumatoid arthritis: case control study. BMC Musculoskelet Disord 2013; 14: 147.
25. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, Lee MH, Park JR, Kim H, Rhee EJ, Lee WY, Kim SW, Ryu SH, Keum DG. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928-933.
26. Sun N, Zhang Y, Tian JL, Wang H. Relationship between uric acid and arterial stiffness in the elderly with metabolic syndrome components. Chin Med J (Engl) 2013; 126: 3097-3102.
27. Jaipakdee J, Jiamjarasrangsri W, Lohsoonthorn V, Lertmaharit S. Prevalence of metabolic syndrome and its association with serum uric acid levels in Bangkok Thailand. Southeast Asian J Trop Med Public Health 2013; 44: 512-522.
28. Gill A, Kukreja S, Malhotra N, Chhabra N. Correlation of the serum insulin and the serum uric Acid levels with the glycated haemoglobin levels in the patients of type 2 diabetes mellitus. J Clin Diagn Res 2013; 7: 1295-1297.
29. Dessein PH, Christian BF, Woodiwiss AJ, Norton GR, Solomon A. Public healthcare attendance associates with enhanced conventional and non-conventional atherosclerotic cardiovascular disease risk burdens in established rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 230-237.
30. Toms TE, Panoulas VF, John H, Douglas KMJ, Kitas GD. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60-more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther 2009; 11: R110.
31. Raterman HG, Voskuyl AE, Dijkmans BAC, Nurmohamed MT. Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome. Arthritis Res Ther 2009; 11: 413.
32. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Bechir M, Spieker LE, Neidhart M, Michel BA, Gay RE, Luscher TF, Gay S, Ruschitzka F. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Cir-culation 2002; 106: 2184-2187.
33. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004; 51: 447-450.
34. Toms TE, Panoulas VF, Douglas KMJ, Griffiths HR, Kitas GD. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2008; 10: R145.